$IMNM
Immunome Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022012344 Filed on August 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.329M $3.209M $3.576M
YoY Change 3.71% 28.0% 86.25%
% of Gross Profit
Research & Development $5.225M $5.717M $8.078M
YoY Change 15.78% 76.83% 308.19%
% of Gross Profit
Depreciation & Amortization $103.0K $113.0K $111.0K
YoY Change -63.99% -33.92% -36.93%
% of Gross Profit
Operating Expenses $8.534M $8.926M $11.65M
YoY Change 10.5% 55.51% 199.05%
Operating Profit -$8.534M -$8.926M -$11.65M
YoY Change 10.5% 55.51% 199.05%
Interest Expense $1.000K $2.000K $1.000K
YoY Change -133.33% -300.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$8.533M -$8.924M -$11.65M
YoY Change 10.53% 70.27% 198.79%
Income Tax
% Of Pretax Income
Net Earnings -$8.533M -$8.924M -$11.70M
YoY Change 10.53% 70.27% 200.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$0.74 -$0.96
Diluted Earnings Per Share -$0.75 -$0.74 -$0.96
COMMON SHARES
Basic Shares Outstanding 12.13M 12.13M 12.12M
Diluted Shares Outstanding 12.13M 12.13M 12.12M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.08M $34.65M $42.88M
YoY Change -51.86% -42.09% 18.19%
Cash & Equivalents $27.08M $34.65M $42.88M
Short-Term Investments
Other Short-Term Assets $2.161M $2.949M $2.629M
YoY Change -56.32% -1.24% -45.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $29.24M $37.60M $46.30M
YoY Change -52.22% -40.14% 12.64%
LONG-TERM ASSETS
Property, Plant & Equipment $704.0K $807.0K $753.0K
YoY Change -26.74% -34.18% -45.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $432.0K $432.0K $482.0K
YoY Change 6.14% 332.0% 382.0%
Total Long-Term Assets $1.307M $1.421M $1.425M
YoY Change -4.46% 7.16% -4.1%
TOTAL ASSETS
Total Short-Term Assets $29.24M $37.60M $46.30M
Total Long-Term Assets $1.307M $1.421M $1.425M
Total Assets $30.55M $39.02M $47.73M
YoY Change -51.17% -39.17% 12.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.139M $5.259M $3.890M
YoY Change -4.21% 193.8% 31.51%
Accrued Expenses $4.230M $3.359M $5.817M
YoY Change -5.41% 99.11% 397.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.369M $8.618M $9.707M
YoY Change -5.1% 144.76% 112.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $93.00K $124.0K $147.0K
YoY Change 4033.33% 1370.0%
Total Long-Term Liabilities $93.00K $124.0K $147.0K
YoY Change 4033.33% 9.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.369M $8.618M $9.707M
Total Long-Term Liabilities $93.00K $124.0K $147.0K
Total Liabilities $7.462M $8.742M $9.854M
YoY Change -3.9% 148.07% 109.21%
SHAREHOLDERS EQUITY
Retained Earnings -$108.2M -$99.70M -$90.80M
YoY Change 51.75% 57.01% 55.75%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.08M $30.28M $37.87M
YoY Change
Total Liabilities & Shareholders Equity $30.55M $39.02M $47.73M
YoY Change -51.17% -39.17% 12.06%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$8.533M -$8.924M -$11.70M
YoY Change 10.53% 70.27% 200.0%
Depreciation, Depletion And Amortization $103.0K $113.0K $111.0K
YoY Change -63.99% -33.92% -36.93%
Cash From Operating Activities -$7.571M -$8.060M -$6.376M
YoY Change 82.65% 115.74% 80.37%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$170.0K $6.000K
YoY Change -100.0% 1788.89% -80.65%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$170.0K -$6.000K
YoY Change -100.0% 1788.89% -80.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 32.00K
YoY Change -100.0% -100.0% -57.89%
NET CHANGE
Cash From Operating Activities -7.571M -8.060M -6.376M
Cash From Investing Activities 0.000 -170.0K -6.000K
Cash From Financing Activities 0.000 0.000 32.00K
Net Change In Cash -7.571M -8.230M -6.350M
YoY Change 111.13% -134.94% 81.95%
FREE CASH FLOW
Cash From Operating Activities -$7.571M -$8.060M -$6.376M
Capital Expenditures $0.00 -$170.0K $6.000K
Free Cash Flow -$7.571M -$7.890M -$6.382M
YoY Change 83.81% 111.7% 78.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12127385
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11456991
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12125156
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11051185
dei Entity Central Index Key
EntityCentralIndexKey
0001472012
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12127385
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12110373
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34649000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49229000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
200000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39580
dei Entity Registrant Name
EntityRegistrantName
Immunome, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Shell Company
EntityShellCompany
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12127385
dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
321-3700
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
IMNM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2949000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
37598000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
56638000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
807000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
855000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
182000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q2 us-gaap Deferred Costs
DeferredCosts
332000
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
332000
CY2022Q2 us-gaap Assets
Assets
39019000
CY2021Q4 us-gaap Assets
Assets
57925000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5259000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3077000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3359000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8618000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9728000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
124000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12000
CY2022Q2 us-gaap Liabilities
Liabilities
8742000
CY2021Q4 us-gaap Liabilities
Liabilities
9740000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12127385
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12110373
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
129958000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
127289000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99682000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79105000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30277000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39019000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57925000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5717000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3233000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13795000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5212000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3209000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2507000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6785000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4425000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
8926000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
5740000
us-gaap Operating Expenses
OperatingExpenses
20580000
us-gaap Operating Expenses
OperatingExpenses
9637000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8926000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5740000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20580000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9637000
CY2021Q2 us-gaap Other Income
OtherIncome
500000
us-gaap Other Income
OtherIncome
500000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2000
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8924000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5241000
us-gaap Net Income Loss
NetIncomeLoss
-20577000
us-gaap Net Income Loss
NetIncomeLoss
-9139000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12127385
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11456991
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12125156
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11051185
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37874000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1327000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8924000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30277000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2637000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
us-gaap Net Income Loss
NetIncomeLoss
-9139000
us-gaap Net Income Loss
NetIncomeLoss
-20577000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
60617000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
596000
imnm Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
26404000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1074000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30277000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
37883000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
596000
CY2021Q2 imnm Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
26404000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
749000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
801000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5241000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
906000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
60617000
us-gaap Net Income Loss
NetIncomeLoss
-20577000
us-gaap Net Income Loss
NetIncomeLoss
-9139000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
224000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
351000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
33000
us-gaap Share Based Compensation
ShareBasedCompensation
2637000
us-gaap Share Based Compensation
ShareBasedCompensation
1074000
imnm Deferred Rent
DeferredRent
-12000
imnm Deferred Rent
DeferredRent
-3000
imnm Forgiveness Of Ppp Loan
ForgivenessOfPppLoan
-500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4460000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-142000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2182000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
486000
imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-3342000
imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
313000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-41000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14436000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7276000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
176000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-176000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39000
imnm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
27000000
imnm Payments Of Common Stock And Warrants Issuance Costs
PaymentsOfCommonStockAndWarrantsIssuanceCosts
486000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
906000
imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
69000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27378000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14580000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20063000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34749000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59929000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
215000
imnm Offering Cost In Accounts Payable
OfferingCostInAccountsPayable
110000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000
us-gaap Net Income Loss
NetIncomeLoss
-20600000
us-gaap Net Income Loss
NetIncomeLoss
-9100000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99700000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the expected volatility used to estimate fair value of stock options and accrued research and development expenses. Estimates and assumptions are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34649000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59829000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
100000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34749000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59929000
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2022Q2 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3835756
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3378217
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2020Q1 imnm Refundable Employee Retention Credit
RefundableEmployeeRetentionCredit
800000
imnm Contra Research And Development Expense
ContraResearchAndDevelopmentExpense
600000
CY2022Q2 imnm Contra Research And Development Expense
ContraResearchAndDevelopmentExpense
600000
imnm Contra General And Administrative Expense
ContraGeneralAndAdministrativeExpense
200000
imnm Contra Expenses
ContraExpenses
0
CY2021Q2 imnm Contra Expenses
ContraExpenses
0
CY2022Q2 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2205000
CY2021Q4 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
0
CY2022Q2 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
847000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
830000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2019000
CY2022Q2 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
501000
CY2021Q4 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
586000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
528000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
492000
CY2022Q2 imnm Reimbursement Receivable Current
ReimbursementReceivableCurrent
243000
CY2021Q4 imnm Reimbursement Receivable Current
ReimbursementReceivableCurrent
2674000
CY2021Q4 imnm Unbilled Reimbursement Receivable Current
UnbilledReimbursementReceivableCurrent
1638000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2949000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
227000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
66000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
317000
CY2022Q2 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
22000
CY2021Q4 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
2021000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3359000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2021Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2840000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
932000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1246000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
134000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2021Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2022Q2 imnm Collaborative Arrangements Product Development And Regulatory Approval Milestone Payments Payable
CollaborativeArrangementsProductDevelopmentAndRegulatoryApprovalMilestonePaymentsPayable
2600000
CY2022Q2 imnm Collaborative Arrangements Commercial Milestone Payments Payable
CollaborativeArrangementsCommercialMilestonePaymentsPayable
1500000
imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
100000
CY2022Q2 imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
100000
imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
0
CY2021Q2 imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
0
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y6M
imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2021Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1327000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
749000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2637000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1074000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.856
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.831
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
CY2022Q2 imnm Fair Value Of Common Stock
FairValueOfCommonStock
3.64
CY2021Q2 imnm Fair Value Of Common Stock
FairValueOfCommonStock
25.60

Files In Submission

Name View Source Status
0001558370-22-012344-index-headers.html Edgar Link pending
0001558370-22-012344-index.html Edgar Link pending
0001558370-22-012344.txt Edgar Link pending
0001558370-22-012344-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220630.xsd Edgar Link pending
tmb-20220630x10q.htm Edgar Link pending
tmb-20220630x10q_htm.xml Edgar Link completed
tmb-20220630xex10d1.htm Edgar Link pending
tmb-20220630xex10d1001.jpg Edgar Link pending
tmb-20220630xex31d1.htm Edgar Link pending
tmb-20220630xex31d2.htm Edgar Link pending
tmb-20220630xex32d1.htm Edgar Link pending
tmb-20220630xex32d2.htm Edgar Link pending
tmb-20220630_cal.xml Edgar Link unprocessable
tmb-20220630_def.xml Edgar Link unprocessable
tmb-20220630_lab.xml Edgar Link unprocessable
tmb-20220630_pre.xml Edgar Link unprocessable